Literature DB >> 21064130

Mapping mouse IL-13 binding regions using structure modeling, molecular docking, and high-density peptide microarray analysis.

Satish K Madala1, Michael A Dolan, Deepak Sharma, Thirumalai R Ramalingam, Mark S Wilson, Margaret M Mentink-Kane, Daniel C Masison, Thomas A Wynn.   

Abstract

Interleukin-13 is a Th2-associated cytokine responsible for many pathological responses in allergic asthma including mucus production, inflammation, and extracellular matrix remodeling. In addition, IL-13 is required for immunity to many helminth infections. IL-13 signals via the type-II IL-4 receptor, a heterodimeric receptor of IL-13Rα1 and IL-4Rα, which is also used by IL-4. IL-13 also binds to IL-13Rα2, but with much higher affinity than the type-II IL-4 receptor. Binding of IL-13 to IL-13Rα2 has been shown to attenuate IL-13 signaling through the type-II IL-4 receptor. However, molecular determinants that dictate the specificity and affinity of mouse IL-13 for the different receptors are largely unknown. Here, we used high-density overlapping peptide arrays, structural modeling, and molecular docking methods to map IL-13 binding sequences on its receptors. Predicted binding sequences on mouse IL-13Rα1 and IL-13Rα2 were in agreement with the reported human IL-13 receptor complex structures and site-directed mutational analysis. Novel structural differences were identified between IL-13 receptors, particularly at the IL-13 binding interface. Notably, additional binding sites were observed for IL-13 on IL-13Rα2. In addition, the identification of peptide sequences that are unique to IL-13Rα1 allowed us to generate a monoclonal antibody that selectively binds IL-13Rα1. Thus, high-density peptide arrays combined with molecular docking studies provide a novel, rapid, and reliable method to map cytokine-receptor interactions that may be used to generate signaling and decoy receptor-specific antagonists.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21064130      PMCID: PMC3005206          DOI: 10.1002/prot.22881

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  25 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Protein-protein docking with backbone flexibility.

Authors:  Chu Wang; Philip Bradley; David Baker
Journal:  J Mol Biol       Date:  2007-08-02       Impact factor: 5.469

3.  IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts.

Authors:  Allison-Lynn Andrews; Tosia Nasir; Fabio Bucchieri; John W Holloway; Stephen T Holgate; Donna E Davies
Journal:  J Allergy Clin Immunol       Date:  2006-09-08       Impact factor: 10.793

4.  Characterization of the interaction between interleukin-13 and interleukin-13 receptors.

Authors:  Kazuhiko Arima; Kazuo Sato; Go Tanaka; Sachiko Kanaji; Tohru Terada; Eijiro Honjo; Ryota Kuroki; Yo Matsuo; Kenji Izuhara
Journal:  J Biol Chem       Date:  2005-05-03       Impact factor: 5.157

5.  Interleukin-13: central mediator of allergic asthma.

Authors:  M Wills-Karp; J Luyimbazi; X Xu; B Schofield; T Y Neben; C L Karp; D D Donaldson
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

6.  Requirement for IL-13 independently of IL-4 in experimental asthma.

Authors:  G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

7.  Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain.

Authors:  Thirumalai R Ramalingam; John T Pesce; Faruk Sheikh; Allen W Cheever; Margaret M Mentink-Kane; Mark S Wilson; Sean Stevens; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Joseph F Urban; Raymond P Donnelly; Thomas A Wynn
Journal:  Nat Immunol       Date:  2007-12-09       Impact factor: 25.606

8.  IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice.

Authors:  Mark S Wilson; Eldad Elnekave; Margaret M Mentink-Kane; Marcus G Hodges; John T Pesce; Thirumalai R Ramalingam; Robert W Thompson; Masahito Kamanaka; Richard A Flavell; Andrea Keane-Myers; Allen W Cheever; Thomas A Wynn
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 9.  Pulmonary fibrosis: pathogenesis, etiology and regulation.

Authors:  M S Wilson; T A Wynn
Journal:  Mucosal Immunol       Date:  2009-01-07       Impact factor: 7.313

10.  Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease.

Authors:  B Beghé; I P Hall; S G Parker; M F Moffatt; A Wardlaw; M J Connolly; L M Fabbri; C Ruse; I Sayers
Journal:  Allergy       Date:  2009-10-01       Impact factor: 13.146

View more
  3 in total

1.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Authors:  Brijendra Singh; Rajesh K Kasam; Vishwaraj Sontake; Thomas A Wynn; Satish K Madala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

Review 2.  Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease.

Authors:  Steven J Van Dyken; Richard M Locksley
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

Review 3.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.